天邦食品(002124) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥1,887,600,942.78, representing a 51.60% increase compared to ¥1,245,086,754.50 in the same period last year[10] - Net profit attributable to shareholders was ¥476,277,806.84, a significant turnaround from a loss of ¥335,287,082.36, marking a 242.05% increase[10] - Basic earnings per share improved to ¥0.41, compared to a loss of ¥0.29 per share in the same quarter last year, reflecting a 241.62% increase[10] - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching ¥480,560,257.15, compared to a loss of ¥282,065,636.07, marking a 270.37% increase[10] - The total operating revenue for the first quarter reached ¥1,887,600,942.78, a significant increase from ¥1,245,086,754.50 in the previous period, representing a growth of approximately 51.6%[60] - The net profit for the current period is 476,150,381.96, a significant recovery from a net loss of -336,196,101.91 in the previous period[66] - The total profit for the current period is 477,927,111.87, compared to a total loss of -335,255,206.42 in the previous period[66] - The total comprehensive income for the current period is 476,088,210.42, compared to -337,129,612.05 in the previous period, showing a significant turnaround[69] Cash Flow - The net cash flow from operating activities reached ¥415,236,595.76, a remarkable increase of 1,024.68% from a negative cash flow of ¥44,905,739.77 in the previous year[10] - Cash inflow from operating activities reached 2,127,793,051.68 CNY, compared to 1,437,616,179.32 CNY in the prior period, indicating a significant increase[77] - The net cash flow from operating activities was 415,236,595.76 CNY, a turnaround from -44,905,739.77 CNY in the previous year[80] - The cash inflow from sales of goods and services was 1,977,962,970.79 CNY, significantly higher than 1,231,017,702.45 CNY in the prior period[77] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,313,302,849.56, up 10.34% from ¥7,534,383,259.18 at the end of the previous year[10] - The total liabilities increased to ¥4,938,984,275.48 from ¥4,636,152,895.52, reflecting a rise of about 6.5%[51] - The total equity attributable to shareholders of the parent company rose to ¥3,358,153,903.83, up from ¥2,881,871,430.52, indicating an increase of approximately 16.5%[51] - The total current liabilities increased to ¥2,530,355,498.56 from ¥2,465,891,163.17, showing a growth of about 2.6%[55] - The total current assets amounted to CNY 2,194,856,781.25 as of December 31, 2019, remaining unchanged as of January 1, 2020[91] - Total non-current assets were CNY 5,339,526,477.93 as of December 31, 2019, also unchanged as of January 1, 2020[91] - Total assets reached CNY 7,534,383,259.18 as of December 31, 2019, consistent with January 1, 2020[91] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 60,646, indicating a broad shareholder base[15] - The top shareholder, Zhang Banghui, held 24.75% of the shares, with a total of 286,953,918 shares, indicating strong insider ownership[15] Operational Metrics - Operating income increased by 51.6% year-on-year, mainly due to a significant rise in pig sales prices[24] - Accounts receivable increased by 64.5% compared to the beginning of the period, mainly due to sales of aquatic feed being within the credit period[24] - Prepayments increased by 69.9% compared to the beginning of the period, primarily due to the expansion of breeding scale and increased advance payments[24] - Production biological assets increased by 50.7% compared to the beginning of the period, mainly due to an increase in breeding stock[24] Expenses and Income - Other income decreased by 58% year-on-year, mainly due to a reduction in government subsidies received[24] - Investment income decreased by 64.1% year-on-year, primarily due to a decline in equity method investment income[24] - Tax expenses increased by 88.8% year-on-year, mainly due to an increase in pre-tax profits from vaccine products[24] - Credit impairment losses increased by 66.7% year-on-year, attributed to a greater increase in accounts receivable compared to the same period[24] - Research and development expenses decreased to 18,110,296.61 from 23,339,844.71, a reduction of approximately 22.4%[63] - The financial expenses increased to 37,998,627.31 from 31,476,081.20, representing an increase of about 20.1%[63] - The investment income for the current period is 600,009.81, down from 1,672,656.29 in the previous period, indicating a decline of approximately 64.1%[63]